What is the future of stroke prevention?: Debate: Polypill versus personalized risk factor modification

Stroke

Volumn 41, Issue 10 SUPPL. 1, 2010, Pages

  Kernan, Walter N ^a   Launer, Lenore J ^b   Goldstein, Larry B ^c  

^a YALE UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cerebrovascular disorders; primary prevention

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ATENOLOL; ATORVASTATIN; PRAVASTATIN; ROSUVASTATIN; VALSARTAN;

BLOOD PRESSURE REGULATION; BRAIN ISCHEMIA; COMPARATIVE STUDY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG COMBINATION; DRUG COST; DRUG SAFETY; HUMAN; LIFESTYLE MODIFICATION; PHARMACODYNAMICS; PILL; POLYPILL; PRIORITY JOURNAL; RISK FACTOR; STROKE; UNITED STATES; ECONOMICS; FORECASTING; PRIMARY PREVENTION;

FORECASTING; HUMANS; PRIMARY PREVENTION; RISK FACTORS; STROKE;

EID: 77957983678     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.592022     Document Type: Conference Paper

References (30)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mus-solino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoll S, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121:e46 -215.
2. Gorelick PB. Stroke prevention: an opportunity for efficient utilization of health care resources during the coming decade. Stroke. 1994;25:220-224.
3. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419.
4. Narayan KM, Mensah GA, Sorensen S, Cheng YJ, Vinicor F, Engelgau MM, Williamson DF. Combination pharmacotherapy for cardiovascular disease prevention: threat or opportunity for public health? Am Journal of Preventive Medicine. 2005;29(suppl 1):134-138.
5. Centers for Disease Control and Prevention. Cigarette smoking among adults-United States, 2006. Morbidity and Mortality Weekly Report. 2007;56:1150-1161.
6. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, Degraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke. 2006;37:1583-1633.
7. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
8. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemi-ological studies. BMJ. 2009;338:1245-1253.
9. Wald NJ, Wald DS. The polypill concept. Heart. 2010;96:1-4.
10. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361:1149-1158. (Pubitemid 36398384)
11. Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, Gutnikov SA, Edwards P, Mant D, Sackley CM, Farmer A, Sandercock PA, Dennis MS, Warlow CP, Bamford JM, Anslow P. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet. 2004;363:1925-1933.
12. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH, Messerli FH, Oparil S, Schork MA. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685-1697.
13. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus amlodipine or hydro-chlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
14. Poulter NR, Wedel H, Dahlof B, Sever PS, Beevers DG, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, Pocock S. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366:907-913.
15. Kaplan NM. The ASCOT trial: a closer look. J Hypertens. 2006;24: 211-214.
16. Amarenco P. Polypill strategy vs. prevention clinics for stroke prevention. Cerebrovascular Diseases. 2006;21:35-40.
17. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascuar disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373:1849-1860.
18. The Indian Polycaps Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373:1341-1351.
19. Reddy KS. The preventive polypill: much promise, insufficient evidence. N Engl J Med. 2007;356:212.
20. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, Sowers MR. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med. 2008;168:1617-1624.
21. Cook S, Auinger P, Li C, Ford ES. Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999-2002. Journal of Pediatrics. 2008;152:165-170.
22. Borer JS, Simon LS. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Arthritis Research & Therapy. 2005;7(suppl 4):S14-S22.
23. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmeno-pausal hormone replacement therapy: scientific review. JAMA. 2002;288: 872-881.
24. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572
25. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545-2559.
26. Krumholz HM, Lee TH. Redefining quality-implications of recent clinical trials. N Engl J Med. 2008;358:2537-2539.
27. Chiuve SE, Rexrode KM, Spiegelman D, Logroscino G, Manson JE, Rimm EB. Primary prevention of stroke by healthy lifestyle. Circulation. 2008;118:947-954.
28. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677-1686.
29. Franco OH, Steyerberg EW, de Laet C. The polypill: at what price would it become cost effective? J Epidemiol Community Health. 2006;60: 213-217.
30. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Circulation. 2008;118: 576-585.